Covid-19大流行期间精神障碍患者的再住院率:口服与长效注射抗精神病药物

IF 2 Q3 CLINICAL NEUROLOGY
Tonći Mastelić, Tonka Borovina Marasović, Mihaela Rakušić, Dinko Martinović, Davor Lasić, Boran Uglešić, Trpimir Glavina
{"title":"Covid-19大流行期间精神障碍患者的再住院率:口服与长效注射抗精神病药物","authors":"Tonći Mastelić,&nbsp;Tonka Borovina Marasović,&nbsp;Mihaela Rakušić,&nbsp;Dinko Martinović,&nbsp;Davor Lasić,&nbsp;Boran Uglešić,&nbsp;Trpimir Glavina","doi":"10.36131/cnfioritieditore20220603","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The superiority of long-acting injectable antipsychotics (LAIs) versus oral antipsychotics is often emphasized, even in terms of adherence and rehospitaliza-tion rates. As such, LAIs are particularly recommended during the COVID-19 pandemic. The goal of our research was to determine whether there are differences in the number of rehospitalizations in patients treated for schizophrenia, schizophrenia-like disorders, and delusional states (psychotic disorders) with LAI antispychotics versus oral antispychotics.</p><p><strong>Method: </strong>Subjects with schizophrenia, schizophrenia-like disorders and delusional states participated in our retrospective study. 124 subjects were treated with oral anti-psychotics, while 72 received LAIs along with oral antipsychotics. We collected their sociodemographic data and psychiatric history data. Our main outcome measure was the number of rehospitalizations.</p><p><strong>Results: </strong>Statistical analysis showed that the studied groups did not differ according to sociodemographic parameters, except that in the group of patients with LAIs there was a significantly higher percentage of men (65 (52.4) vs 50 (69.4), p=0.029)). Also, the groups do not differ according to the psychiatric history data. There is no difference in the duration of the current hospitalization nor in the composition of the patients, considering the order of the current hospitalization. The difference in the number of rehospitalizations is not significant neither in the first year of follow-up (p=0.144), nor in the second (p=0.142), nor after two years of follow-up (p=0.083).</p><p><strong>Conclusions: </strong>Our research has shown that there is no difference in the number of rehospitalizations in patients with schizophrenia, schizophrenia-like disorders and delusional states, considering whether they take oral antipsychotics or they also take LAIs along with them. We can therefore conclude that it is particularly important to work on improving patient adherence. We must make psychiatrists aware that the pandemic, like other threats, can be our ally in improving adherence (\"perceived threat as a health belief\").</p>","PeriodicalId":46700,"journal":{"name":"Clinical Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807113/pdf/","citationCount":"1","resultStr":"{\"title\":\"Rehospitalization Rates Among Patients with Psychotic Disorders During Covid-19 Pandemic: Oral Versus Long-Acting Injectable Antipsychotics.\",\"authors\":\"Tonći Mastelić,&nbsp;Tonka Borovina Marasović,&nbsp;Mihaela Rakušić,&nbsp;Dinko Martinović,&nbsp;Davor Lasić,&nbsp;Boran Uglešić,&nbsp;Trpimir Glavina\",\"doi\":\"10.36131/cnfioritieditore20220603\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The superiority of long-acting injectable antipsychotics (LAIs) versus oral antipsychotics is often emphasized, even in terms of adherence and rehospitaliza-tion rates. As such, LAIs are particularly recommended during the COVID-19 pandemic. The goal of our research was to determine whether there are differences in the number of rehospitalizations in patients treated for schizophrenia, schizophrenia-like disorders, and delusional states (psychotic disorders) with LAI antispychotics versus oral antispychotics.</p><p><strong>Method: </strong>Subjects with schizophrenia, schizophrenia-like disorders and delusional states participated in our retrospective study. 124 subjects were treated with oral anti-psychotics, while 72 received LAIs along with oral antipsychotics. We collected their sociodemographic data and psychiatric history data. Our main outcome measure was the number of rehospitalizations.</p><p><strong>Results: </strong>Statistical analysis showed that the studied groups did not differ according to sociodemographic parameters, except that in the group of patients with LAIs there was a significantly higher percentage of men (65 (52.4) vs 50 (69.4), p=0.029)). Also, the groups do not differ according to the psychiatric history data. There is no difference in the duration of the current hospitalization nor in the composition of the patients, considering the order of the current hospitalization. The difference in the number of rehospitalizations is not significant neither in the first year of follow-up (p=0.144), nor in the second (p=0.142), nor after two years of follow-up (p=0.083).</p><p><strong>Conclusions: </strong>Our research has shown that there is no difference in the number of rehospitalizations in patients with schizophrenia, schizophrenia-like disorders and delusional states, considering whether they take oral antipsychotics or they also take LAIs along with them. We can therefore conclude that it is particularly important to work on improving patient adherence. We must make psychiatrists aware that the pandemic, like other threats, can be our ally in improving adherence (\\\"perceived threat as a health belief\\\").</p>\",\"PeriodicalId\":46700,\"journal\":{\"name\":\"Clinical Neuropsychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807113/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Neuropsychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36131/cnfioritieditore20220603\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropsychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36131/cnfioritieditore20220603","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:长效注射抗精神病药物(LAIs)相对于口服抗精神病药物的优势经常被强调,甚至在依从性和再住院率方面也是如此。因此,在2019冠状病毒病大流行期间,特别建议使用lai。我们研究的目的是确定在治疗精神分裂症、精神分裂症样障碍和妄想状态(精神障碍)的患者中,使用LAI抗精神病药物与口服抗精神病药物的再住院次数是否存在差异。方法:对精神分裂症、精神分裂症样障碍和妄想患者进行回顾性研究。124例患者口服抗精神病药物治疗,72例患者在服用抗精神病药物的同时接受LAIs治疗。我们收集了他们的社会人口统计数据和精神病史数据。我们的主要结局指标是再住院的次数。结果:统计分析显示,各组在社会人口学参数上没有差异,但在LAIs患者组中,男性的比例明显高于男性(65 (52.4)vs 50 (69.4), p=0.029)。此外,根据精神病史数据,两组没有差异。考虑到当前住院的顺序,当前住院的持续时间和患者的构成没有差异。随访第一年(p=0.144)、随访第二年(p=0.142)、随访2年后(p=0.083)再住院次数差异均无统计学意义。结论:我们的研究表明,考虑到精神分裂症、精神分裂症样障碍和妄想状态患者是否服用口服抗精神病药物或同时服用LAIs,其再住院次数没有差异。因此,我们可以得出结论,提高患者的依从性尤为重要。我们必须让精神科医生认识到,大流行病和其他威胁一样,可以成为我们提高依从性("将感知到的威胁视为一种健康信念")的盟友。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Rehospitalization Rates Among Patients with Psychotic Disorders During Covid-19 Pandemic: Oral Versus Long-Acting Injectable Antipsychotics.

Rehospitalization Rates Among Patients with Psychotic Disorders During Covid-19 Pandemic: Oral Versus Long-Acting Injectable Antipsychotics.

Objective: The superiority of long-acting injectable antipsychotics (LAIs) versus oral antipsychotics is often emphasized, even in terms of adherence and rehospitaliza-tion rates. As such, LAIs are particularly recommended during the COVID-19 pandemic. The goal of our research was to determine whether there are differences in the number of rehospitalizations in patients treated for schizophrenia, schizophrenia-like disorders, and delusional states (psychotic disorders) with LAI antispychotics versus oral antispychotics.

Method: Subjects with schizophrenia, schizophrenia-like disorders and delusional states participated in our retrospective study. 124 subjects were treated with oral anti-psychotics, while 72 received LAIs along with oral antipsychotics. We collected their sociodemographic data and psychiatric history data. Our main outcome measure was the number of rehospitalizations.

Results: Statistical analysis showed that the studied groups did not differ according to sociodemographic parameters, except that in the group of patients with LAIs there was a significantly higher percentage of men (65 (52.4) vs 50 (69.4), p=0.029)). Also, the groups do not differ according to the psychiatric history data. There is no difference in the duration of the current hospitalization nor in the composition of the patients, considering the order of the current hospitalization. The difference in the number of rehospitalizations is not significant neither in the first year of follow-up (p=0.144), nor in the second (p=0.142), nor after two years of follow-up (p=0.083).

Conclusions: Our research has shown that there is no difference in the number of rehospitalizations in patients with schizophrenia, schizophrenia-like disorders and delusional states, considering whether they take oral antipsychotics or they also take LAIs along with them. We can therefore conclude that it is particularly important to work on improving patient adherence. We must make psychiatrists aware that the pandemic, like other threats, can be our ally in improving adherence ("perceived threat as a health belief").

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Neuropsychiatry
Clinical Neuropsychiatry CLINICAL NEUROLOGY-
CiteScore
11.10
自引率
1.60%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信